Sprouty4 mRNA variants and protein expressions in breast and lung‑derived cells

Doriguzzi,Angelina; Salhi,Jihen; Sutterlüty‑Fall,Hedwig

doi:10.3892/ol.2016.5216

Sprouty4 mRNA variants and protein expressions in breast and lung‑derived cells

Authors:
- Angelina Doriguzzi
- Jihen Salhi
- Hedwig Sutterlüty‑Fall
View Affiliations

Affiliations: Institute of Cancer Research, Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, A‑1090 Vienna, Austria
Published online on: September 30, 2016 https://doi.org/10.3892/ol.2016.5216
Pages: 4161-4166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sprouty proteins are modulators of mitogen‑induced signalling processes and are therefore hypothesized to affect malignant diseases. As a member of the Sprouty family, Sprouty4 has been previously shown to function as a tumour suppressor in lung and breast cancer. The present study analysed the expression of two known Sprouty4 splice variants in cells established from malignant and normal lung and breast tissues using semi-quantitative reverse transcription‑polymerase chain reaction and immunoblotting. The results indicated that the expression of the two messenger RNA (mRNA) variants was reduced in the cells derived from malignant tissue in comparison to the normal counterparts. Although the expression of the two splice variants were associated in both tissue types, on average, the relative expression of the longer variant was slightly increased in malignant cells compared with normal tissues. Notably, the protein levels reflected the expression observed at the mRNA level only in breast‑derived cells. Contrarily, with regards to the measured mRNA levels, Sprouty4 protein was disproportional augmented in lung cells known to harbour the mutated K‑Ras gene.

View Figures

View References

1	Hahn WC and Weinberg RA: Rules for making human tumor cells. N Engl J Med. 347:1593–1603. 2002. View Article : Google Scholar : PubMed/NCBI
2	Hommes DW, Peppelenbosch MP and van Deventer SJ: Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 52:144–151. 2003. View Article : Google Scholar : PubMed/NCBI
3	Freeman M: Feedback control of intercellular signalling in development. Nature. 408:313–319. 2000. View Article : Google Scholar : PubMed/NCBI
4	Casci T, Vinós J and Freeman M: Sprouty, an intracellular inhibitor of Ras signaling. Cell. 96:655–665. 1999. View Article : Google Scholar : PubMed/NCBI
5	Hacohen N, Kramer S, Sutherland D, Hiromi Y and Krasnow MA: sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 92:253–263. 1998. View Article : Google Scholar : PubMed/NCBI
6	Guy GR, Jackson RA, Yusoff P and Chow SY: Sprouty proteins: Modified modulators, matchmakers or missing links? J Endocrinol. 203:191–202. 2009. View Article : Google Scholar : PubMed/NCBI
7	Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T, McMahon AP, et al: Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell. 8:229–239. 2005. View Article : Google Scholar : PubMed/NCBI
8	Shim K, Minowada G, Coling DE and Martin GR: Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell. 8:553–564. 2005. View Article : Google Scholar : PubMed/NCBI
9	Taketomi T, Yoshiga D, Taniguchi K, Kobayashi T, Nonami A, Kato R, Sasaki M, Sasaki A, Ishibashi H, Moriyama M, et al: Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia. Nat Neurosci. 8:855–857. 2005. View Article : Google Scholar : PubMed/NCBI
10	Taniguchi K, Ayada T, Ichiyama K, Kohno R, Yonemitsu Y, Minami Y, Kikuchi A, Maehara Y and Yoshimura A: Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signaling. Biochem Biophys Res Commun. 352:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhang S, Lin Y, Itäranta P, Yagi A and Vainio S: Expression of Sprouty genes 1, 2 and 4 during mouse organogenesis. Mech Dev. 109:367–370. 2001. View Article : Google Scholar : PubMed/NCBI
12	Masoumi-Moghaddam S, Amini A and Morris DL: The developing story of Sprouty and cancer. Cancer Metastasis Rev. 33:695–720. 2014. View Article : Google Scholar : PubMed/NCBI
13	Barbáchano A, Ordóñez-Morán P, Garcia JM, Sánchez A, Pereira F, Larriba MJ, Martínez N, Hernández J, Landolfi S, Bonilla F, et al: SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene. 29:4800–4813. 2010. View Article : Google Scholar : PubMed/NCBI
14	Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M and Khare S: Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: Sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 29:5241–5253. 2010. View Article : Google Scholar : PubMed/NCBI
15	Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R and Kool M: Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 70:762–771. 2010. View Article : Google Scholar : PubMed/NCBI
16	Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M and Berger W: Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res. 5:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
17	McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, Gnanapragasam VJ, Robson CN and Leung HY: Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 24:2166–2174. 2005. View Article : Google Scholar : PubMed/NCBI
18	Fritzsche S, Kenzelmann M, Hoffmann MJ, Müller M, Engers R, Gröne HJ and Schulz WA: Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer. 13:839–849. 2006. View Article : Google Scholar : PubMed/NCBI
19	Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, et al: The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res. 64:6127–6136. 2004. View Article : Google Scholar : PubMed/NCBI
20	Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK and Guy GR: Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 66:2048–2058. 2006. View Article : Google Scholar : PubMed/NCBI
21	Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G and Morris DL: Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. Int J Cancer. 137:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G and Ittmann M: The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 64:4728–4735. 2004. View Article : Google Scholar : PubMed/NCBI
23	Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G and Morris DL: Sprouty 1 predicts prognosis in human epithelial ovarian cancer. Am J Cancer Res. 5:1531–1541. 2015.PubMed/NCBI
24	Rathmanner N, Haigl B, Vanas V, Doriguzzi A, Gsur A and Sutterlüty-Fall H: Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells. FEBS Lett. 587:2597–2605. 2013. View Article : Google Scholar : PubMed/NCBI
25	Jäggi F, Cabrita MA, Perl AK and Christofori G: Modulation of endocrine pancreas development but not beta-cell carcinogenesis by Sprouty4. Mol Cancer Res. 6:468–482. 2008. View Article : Google Scholar : PubMed/NCBI
26	Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA and Winn RA: Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res. 8:833–843. 2010. View Article : Google Scholar : PubMed/NCBI
27	Vanas V, Mühlbacher E, Kral R and Sutterlüty-Fall H: Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour Biol. 35:4447–4456. 2014. View Article : Google Scholar : PubMed/NCBI
28	Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP and Harrison DJ: Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One. 6:e237722011. View Article : Google Scholar : PubMed/NCBI
29	Ding W, Bellusci S, Shi W and Warburton D: Genomic structure and promoter characterization of the human Sprouty4 gene, a novel regulator of lung morphogenesis. Am J Physiol Lung Cell Mol Physiol. 287:52–59. 2004. View Article : Google Scholar
30	Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS and Perera RJ: The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 71:3852–3862. 2011. View Article : Google Scholar : PubMed/NCBI
31	Berger W, Elbling L, Hauptmann E and Micksche M: Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer. 73:84–93. 1997. View Article : Google Scholar : PubMed/NCBI
32	Haigl B, Mayer CE, Siegwart G and Sutterlüty H: Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biol Chem. 391:813–821. 2010. View Article : Google Scholar : PubMed/NCBI
33	Kral RM, Mayer CE, Vanas V, Gsur A and Sutterlüty-Fall H: In non-small cell lung cancer mitogenic signaling leaves Sprouty1 protein levels unaffected. Cell Biochem Funct. 32:96–100. 2014. View Article : Google Scholar : PubMed/NCBI
34	Sirivatanauksorn Y, Sirivatanauksorn V, Srisawat C, Khongmanee A and Tongkham C: Differential expression of sprouty genes in hepatocellular carcinoma. J Surg Oncol. 105:273–276. 2012. View Article : Google Scholar : PubMed/NCBI
35	Wang J, Thompson B, Ren C, Ittmann M and Kwabi-Addo B: Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate. 66:613–624. 2006. View Article : Google Scholar : PubMed/NCBI
36	Doriguzzi A, Haigl B, Gsur A and Sutterlüty-Fall H: The increased Sprouty4 expression in response to serum is transcriptionally controlled by Specific protein 1. Int J Biochem Cell Biol. 64:220–228. 2015. View Article : Google Scholar : PubMed/NCBI
37	Mayer CE, Haigl B, Jantscher F, Siegwart G, Grusch M, Berger W and Sutterlüty H: Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci. 67:3299–3311. 2010. View Article : Google Scholar : PubMed/NCBI
38	So WK, Cheng JC, Liu Y, Xu C, Zhao J, Chang VT and Leung PC: Sprouty4 mediates amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Tumour Biol. 2016. View Article : Google Scholar : PubMed/NCBI
39	Zhang H, Guo Q, Wang X, Wang C, Zhao X and Li M: Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma. Oncol Lett. 11:45–50. 2016.PubMed/NCBI